AU2019241301B2 - Method for large-scale production of lentivirus by using GMP-level serum-free suspension cells - Google Patents

Method for large-scale production of lentivirus by using GMP-level serum-free suspension cells Download PDF

Info

Publication number
AU2019241301B2
AU2019241301B2 AU2019241301A AU2019241301A AU2019241301B2 AU 2019241301 B2 AU2019241301 B2 AU 2019241301B2 AU 2019241301 A AU2019241301 A AU 2019241301A AU 2019241301 A AU2019241301 A AU 2019241301A AU 2019241301 B2 AU2019241301 B2 AU 2019241301B2
Authority
AU
Australia
Prior art keywords
culture
liquid change
cells
transfection
trigger condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019241301A
Other languages
English (en)
Other versions
AU2019241301A1 (en
Inventor
Yi Hong
Ting YAN
Jiangguo YING
Haojie Zhang
Li Zhang
Luyi ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Abelzeta Ltd
Original Assignee
Shanghai Abelzeta Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Abelzeta Ltd filed Critical Shanghai Abelzeta Ltd
Publication of AU2019241301A1 publication Critical patent/AU2019241301A1/en
Assigned to Shanghai CellularBiopharmaceutical Group Ltd. reassignment Shanghai CellularBiopharmaceutical Group Ltd. Request for Assignment Assignors: CELLULAR BIOMEDICINE GROUP HK LIMITED
Assigned to Shanghai AbelZeta Ltd. reassignment Shanghai AbelZeta Ltd. Amend patent request/document other than specification (104) Assignors: SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
Application granted granted Critical
Publication of AU2019241301B2 publication Critical patent/AU2019241301B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/02—Separating microorganisms from the culture medium; Concentration of biomass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/12—Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Sustainable Development (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2019241301A 2018-03-29 2019-03-28 Method for large-scale production of lentivirus by using GMP-level serum-free suspension cells Active AU2019241301B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810273392.7 2018-03-29
CN201810273392.7A CN110317791A (zh) 2018-03-29 2018-03-29 Gmp级无血清悬浮细胞大规模生产慢病毒的方法
PCT/CN2019/080215 WO2019184996A1 (zh) 2018-03-29 2019-03-28 Gmp级无血清悬浮细胞大规模生产慢病毒的方法

Publications (2)

Publication Number Publication Date
AU2019241301A1 AU2019241301A1 (en) 2020-10-22
AU2019241301B2 true AU2019241301B2 (en) 2025-04-17

Family

ID=68058573

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019241301A Active AU2019241301B2 (en) 2018-03-29 2019-03-28 Method for large-scale production of lentivirus by using GMP-level serum-free suspension cells

Country Status (8)

Country Link
US (3) US11845962B2 (https=)
EP (1) EP3778880A4 (https=)
JP (2) JP2021519108A (https=)
KR (1) KR20200136463A (https=)
CN (1) CN110317791A (https=)
AU (1) AU2019241301B2 (https=)
SG (1) SG11202009826PA (https=)
WO (1) WO2019184996A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110317791A (zh) * 2018-03-29 2019-10-11 西比曼生物科技（香港）有限公司 Gmp级无血清悬浮细胞大规模生产慢病毒的方法
CN110894494B (zh) * 2019-11-22 2022-09-27 广西梧州制药（集团）股份有限公司 一种大规模高密度悬浮培养293细胞高产腺病毒的方法
CN113832112A (zh) * 2020-06-24 2021-12-24 重庆精准生物技术有限公司 一种制备慢病毒的混合方法及混合系统
EP4330381A1 (en) * 2021-04-27 2024-03-06 Novartis AG Viral vector production system
CN113265425A (zh) * 2021-05-08 2021-08-17 苏州博腾生物制药有限公司 基于悬浮细胞的car-cd19慢病毒制备工艺
CN114990077A (zh) * 2022-08-01 2022-09-02 深圳市先康达生命科学有限公司 一种慢病毒包装与纯化方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107523555A (zh) * 2016-06-22 2017-12-29 武汉光谷人福生物医药有限公司 获得病毒的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002348151A1 (en) 2001-11-05 2003-05-19 Genvec, Inc. Viral vector production methods and compositions
US20030175688A1 (en) 2002-03-15 2003-09-18 Rukmini Pennathur-Das Method for the purification and production of oncolytic adenoviruses
WO2007095336A2 (en) 2006-02-15 2007-08-23 The Immune Response Corporation Production of hiv
PL2007883T3 (pl) 2006-04-20 2012-07-31 Wyeth Llc Sposób oczyszczania do izolacji oczyszczonego wirusa pęcherzykowatego zapalenia jamy ustnej z hodowli komórkowej
JP2011507523A (ja) 2007-12-21 2011-03-10 ワイス・エルエルシー 遺伝子改変した弱毒化水疱性口内炎ウイルス、組成物およびその使用方法
CN102203242B (zh) 2008-11-03 2013-06-12 克鲁塞尔荷兰公司 产生腺病毒载体的方法
PT2782997T (pt) 2011-11-24 2018-04-09 Genethon Sistema de produção de vetor lentiviral escalável compatível com aplicações farmacêuticas industriais
EP2682168A1 (en) 2012-07-02 2014-01-08 Millipore Corporation Purification of biological molecules
CN103881984A (zh) * 2013-12-06 2014-06-25 深圳市赛百诺基因技术有限公司 无血清悬浮细胞生产重组腺病毒的方法及其药品制剂生产方法
FR3014901B1 (fr) 2013-12-17 2017-06-09 Genethon Procede de purification de virus ou vecteurs viraux enveloppes
CN104371982A (zh) 2014-10-21 2015-02-25 武汉维诺赛生物技术有限公司 一种慢病毒的纯化方法
EP3054007A1 (en) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
CN107043784A (zh) * 2016-02-05 2017-08-15 上海吉凯基因化学技术有限公司 一种慢病毒载体的制备方法
CN107841482B (zh) * 2016-09-21 2021-07-27 上海倍谙基生物科技有限公司 Mdck细胞无血清悬浮培养技术生产h9亚型流感疫苗
CN106434571A (zh) * 2016-10-19 2017-02-22 深圳源兴基因技术有限公司 一种wave无血清培养悬浮细胞制备重组腺病毒的方法
CN106474466B (zh) 2016-12-07 2018-04-13 申联生物医药（上海）股份有限公司 一种口蹄疫疫苗的制备方法
CN107384877B (zh) 2017-08-18 2020-09-08 深圳源兴基因技术有限公司 一种慢病毒的纯化方法
CN107630037A (zh) 2017-10-19 2018-01-26 和元生物技术（上海）股份有限公司 一种获得高纯度腺相关病毒载体的纯化工艺
CN110317832B (zh) 2018-03-28 2022-07-05 西比曼生物科技（香港）有限公司 Gmp级规模化制备重组慢病毒载体的纯化制剂的方法
CN110317791A (zh) * 2018-03-29 2019-10-11 西比曼生物科技（香港）有限公司 Gmp级无血清悬浮细胞大规模生产慢病毒的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107523555A (zh) * 2016-06-22 2017-12-29 武汉光谷人福生物医药有限公司 获得病毒的方法

Also Published As

Publication number Publication date
US20250084386A1 (en) 2025-03-13
EP3778880A4 (en) 2021-12-29
JP2021519108A (ja) 2021-08-10
AU2019241301A1 (en) 2020-10-22
KR20200136463A (ko) 2020-12-07
WO2019184996A1 (zh) 2019-10-03
US20240060053A1 (en) 2024-02-22
US12180513B2 (en) 2024-12-31
US11845962B2 (en) 2023-12-19
EP3778880A1 (en) 2021-02-17
SG11202009826PA (en) 2020-11-27
CN110317791A (zh) 2019-10-11
US20210363497A1 (en) 2021-11-25
JP2024075766A (ja) 2024-06-04

Similar Documents

Publication Publication Date Title
AU2019241301B2 (en) Method for large-scale production of lentivirus by using GMP-level serum-free suspension cells
US20220235371A1 (en) Scalable lentiviral vector production system compatible with industrial pharmaceutical applications
Ausubel et al. Production of CGMP-grade lentiviral vectors
JP2018007671A (ja) 真核細胞の形質導入に有用なウイルスベースのベクター組成物
US12037599B2 (en) Methods and constructs for production of lentiviral vector
WO2022262206A1 (zh) Gmp级逆转录病毒载体的纯化方法与应用
US20250361491A1 (en) Methods of producing an enveloped virus
HK40042109A (en) Method for large-scale production of lentivirus by using gmp-level serum-free suspension cells
CN115916987A (zh) 填充床生物反应器中的慢病毒载体制造方法
AU2012352394B2 (en) Large commercial scale lentiviral vector production system and vectors produced thereby
WO2025219920A1 (en) Methods of producing an enveloped virus
WO2025219924A1 (en) Cell lines overexpressing vesicular stomatitis virus g
WO2025240411A1 (en) Cost-effective and user-friendly viral vector production methodology
HK1255189A1 (en) Scalable lentiviral vector production system compatible with industrial pharmaceutical applications
HK40063602B (zh) 慢病毒载体产生方法及构建体

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SHANGHAI CELLULARBIOPHARMACEUTICAL GROUP LTD.

Free format text: FORMER APPLICANT(S): CELLULAR BIOMEDICINE GROUP HK LIMITED

HB Alteration of name in register

Owner name: SHANGHAI ABELZETA LTD.

Free format text: FORMER NAME(S): SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD.

FGA Letters patent sealed or granted (standard patent)